clarithromycin has been researched along with Coronary Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YC; Li, YD; Yu, BH | 1 |
| Ärnlöv, J; Carlsson, AC; Gluud, C; Hilden, J; Jakobsen, JC; Jensen, GB; Kastrup, J; Kjøller, E; Kolmos, HJ; Larsson, A; Nowak, C; Ruge, T; Sajadieh, A; Winkel, P | 2 |
| Ärnlöv, J; Bring, C; Carlsson, AC; Gluud, C; Hilden, J; Jakobsen, JC; Jensen, GB; Kastrup, J; Kjøller, E; Kolmos, HJ; Larsson, A; Sajadieh, A; Winkel, P; Wuopio, J | 1 |
| Li, C; Li, X; Liu, G; Wang, M; Wang, Z; Zhou, L | 1 |
| Frydendall, N; Gluud, C; Hansen, JF; Hilden, J; Jespersen, CM; Kolmos, HJ | 1 |
| Als-Nielsen, B; Damgaard, M; Gluud, C; Hansen, JF; Hansen, S; Helø, OH; Hildebrandt, P; Hilden, J; Jensen, GB; Jespersen, CM; Kastrup, J; Kjøller, E; Kolmos, HJ; Lind, I; Nielsen, H; Petersen, L | 2 |
| Frandsen, NJ; Galatius, S; Gluud, C; Hansen, JF; Hildebrandt, P; Hilden, J; Jensen, G; Jespersen, CM; Kastrup, J; Kjoller, E; Kolmos, HJ; Winkel, P | 1 |
| Berg, HF; Gielis, SK; Kluytmans, JA; Maraha, B; Peeters, MF; Roholl, PJ; Scheffer, GJ; van der Zee, A | 1 |
| Als-Nielsen, B; Damgaard, M; Fischer Hansen, J; Gluud, C; Hansen, S; Helø, OH; Hildebrandt, P; Hilden, J; Jensen, GB; Jespersen, CM; Kastrup, J; Kjøller, E; Kolmos, HJ; Lind, I; Nielsen, H; Petersen, L | 1 |
| Fitscha, P; Schweeger, I; Sinzinger, H | 1 |
| Alter, P; Maisch, B; Schaefer, JR | 1 |
9 trial(s) available for clarithromycin and Coronary Disease
| Article | Year |
|---|---|
10-Year Associations Between Tumor Necrosis Factor Receptors 1 and 2 and Cardiovascular Events in Patients With Stable Coronary Heart Disease: A CLARICOR (Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease) Trial S
Topics: Aged; Anti-Bacterial Agents; Biomarkers; Cause of Death; Clarithromycin; Coronary Disease; Denmark; Disease Progression; Female; Humans; Incidence; Male; Middle Aged; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2018 |
Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study.
Topics: Aged; Angina, Unstable; Atherosclerosis; Cardiovascular Diseases; Cathepsin B; Cathepsins; Cerebrovascular Disorders; Clarithromycin; Coronary Disease; Denmark; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lysosomes; Male; Middle Aged; Mortality; Myocardial Infarction; Peripheral Vascular Diseases; Proportional Hazards Models; Registries; Risk Factors; Treatment Outcome | 2018 |
Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study.
Topics: Aged; Cardiovascular Diseases; Clarithromycin; Coronary Disease; Endostatins; Female; Humans; Male; Middle Aged; Risk Factors; Single-Blind Method | 2019 |
Compliance with and short-term adverse events from clarithromycin versus placebo in patients with stable coronary heart disease: the CLARICOR trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Coronary Disease; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Patient Compliance; Placebos; Young Adult | 2009 |
Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease.
Topics: Aged; Clarithromycin; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mortality; Treatment Outcome | 2010 |
Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Chlamydophila Infections; Chlamydophila pneumoniae; Clarithromycin; Coronary Disease; Female; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Placebos; Prognosis; Risk Factors | 2010 |
Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease.
Topics: Algorithms; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Confidence Intervals; Coronary Disease; Denmark; Follow-Up Studies; Humans; Inpatients; Myocardial Infarction; Observer Variation; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2012 |
Effect of clarithromycin treatment on Chlamydia pneumoniae in vascular tissue of patients with coronary artery disease: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Bacterial; Chlamydophila pneumoniae; Clarithromycin; Coronary Disease; Coronary Vessels; DNA, Bacterial; Double-Blind Method; Female; Humans; Immunoglobulin G; Male; Middle Aged | 2005 |
Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Confidence Intervals; Coronary Disease; Denmark; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Risk; Survival Analysis | 2008 |
5 other study(ies) available for clarithromycin and Coronary Disease
| Article | Year |
|---|---|
A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Coronary Disease; Disease Progression; Helicobacter pylori; Humans; Peptic Ulcer | 2022 |
Macrolides use and the risk of sudden cardiac death.
Topics: Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Clarithromycin; Coronary Artery Disease; Coronary Disease; Death, Sudden, Cardiac; Erythromycin; Humans; Macrolides; Plaque, Atherosclerotic; Risk Factors; Torsades de Pointes | 2016 |
Clarithromycin in coronary heart disease: excess mortality in the long term.
Topics: Antibiotic Prophylaxis; Clarithromycin; Clinical Trials as Topic; Coronary Disease; Denmark; Humans; Macrolides; Randomized Controlled Trials as Topic | 2006 |
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute-Phase Reaction; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Biomarkers; Breath Tests; Cholesterol, HDL; Cholesterol, LDL; Clarithromycin; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Sulfoxides; Treatment Outcome; Triglycerides; Urea | 2000 |
[Impediment of cellular immune response under treatment with ticlopidine in a patient with Staphylococcus aureus endocarditis].
Topics: Agranulocytosis; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Clarithromycin; Coronary Disease; Drug Therapy, Combination; Echocardiography, Doppler; Endocarditis, Bacterial; Fibrinolytic Agents; Gentamicins; Humans; Imipenem; Immunity, Cellular; Leukocyte Count; Leukocytes; Leukopenia; Male; Middle Aged; Platelet Aggregation Inhibitors; Staphylococcal Infections; Thienamycins; Ticlopidine; Time Factors; Vancomycin | 2000 |